Ascendis Pharma, Inc. (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient endogenous growth hormone secretion (growth hormone deficiency, or GHD).
https://finance.yahoo.com/news/ascendis-pharma-launches-skytrofa-lonapegsomatropin-120000039.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.